InBiose, founded in 2013 as a spinoff from the University of Ghent, is now the biggest private research group in the world of specialty glycan. It is a leading B2B Biotech Company with focus on the development of specialty glycans, in particular Human Milk Oligosaccharides (HMOs) and on developing cost-effective processes for large scale HMO production, based on our proprietary GlycoActives® technology. It has a team of 50 highly skilled and committed, mainly bio-engineers and bio-informatics. InBiose is dedicated to developing specialty glycans that are known to influence health, either directly or indirectly through modulation of the microbiome and the immunity. It has a technology platform based on latest advancements into biotech, bio-informatics and health sciences, which strive to make these specialty glycans available for mainstream uses, minimizing time to market, to the benefit of all.
See also this video about InBiose.
In the Stop Spread Bad Bugs project, InBiose host 2 doctoral candidates working on synthesis, QC and modification of antimicrobial non-digestible oligosaccharides and testing their efficacy during the pathogen-gut interaction.
